A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 pilot study, involving a 48-week treatment period, designed to test the
effectiveness of investigational study drug ARRY-371797 in treating patients with symptomatic
genetic dilated cardiomyopathy due to a lamin A/C gene mutation, and to further evaluate the
drug's safety. Approximately 12 patients from the US will be enrolled in this study.